JP2024539581A - 膀胱への薬物注入のための組成物および方法 - Google Patents

膀胱への薬物注入のための組成物および方法 Download PDF

Info

Publication number
JP2024539581A
JP2024539581A JP2024519605A JP2024519605A JP2024539581A JP 2024539581 A JP2024539581 A JP 2024539581A JP 2024519605 A JP2024519605 A JP 2024519605A JP 2024519605 A JP2024519605 A JP 2024519605A JP 2024539581 A JP2024539581 A JP 2024539581A
Authority
JP
Japan
Prior art keywords
phase
bladder
active agent
composition
plga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539581A5 (cg-RX-API-DMAC7.html
Inventor
アヴィグドール ゴードン、
ナダブ マルキ、
ターヘル ナセル、
ダン トゥイトゥ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trigone Pharma Ltd
Original Assignee
Trigone Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trigone Pharma Ltd filed Critical Trigone Pharma Ltd
Publication of JP2024539581A publication Critical patent/JP2024539581A/ja
Publication of JP2024539581A5 publication Critical patent/JP2024539581A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024519605A 2021-10-17 2022-10-14 膀胱への薬物注入のための組成物および方法 Pending JP2024539581A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256583P 2021-10-17 2021-10-17
US63/256,583 2021-10-17
PCT/IL2022/051090 WO2023062638A1 (en) 2021-10-17 2022-10-14 Compositions and methods for drug instillation into the urinary bladder

Publications (2)

Publication Number Publication Date
JP2024539581A true JP2024539581A (ja) 2024-10-29
JP2024539581A5 JP2024539581A5 (cg-RX-API-DMAC7.html) 2025-08-08

Family

ID=85987609

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519605A Pending JP2024539581A (ja) 2021-10-17 2022-10-14 膀胱への薬物注入のための組成物および方法

Country Status (8)

Country Link
US (1) US20250228767A1 (cg-RX-API-DMAC7.html)
EP (1) EP4415821A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024539581A (cg-RX-API-DMAC7.html)
KR (1) KR20240089461A (cg-RX-API-DMAC7.html)
CN (1) CN118234483A (cg-RX-API-DMAC7.html)
AU (1) AU2022365519A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235477A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023062638A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025180652A1 (en) * 2024-02-28 2025-09-04 Farco-Pharma Gmbh Drug delivery systems for instillation in the urinary bladder comprising active pharmaceutical ingredients

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0687758A (ja) * 1992-07-27 1994-03-29 Rhone Merieux Ｌｈｒｈホルモンおよびその類似体を徐々に放出する微小球体の製造方法と、その微小球体と、それを含む製剤
JPH08157370A (ja) * 1994-12-06 1996-06-18 Banyu Pharmaceut Co Ltd フィナステリド含有徐放性組成物
JP2000511161A (ja) * 1996-05-24 2000-08-29 アンジオテック ファーマシュウティカルズ，インコーポレイテッド 身体通路の疾患を処置または予防するための組成物および方法
JP2001506144A (ja) * 1996-12-02 2001-05-15 ソシエ デ コンシェーユ デ ルシェルシェ エ ダプリカシオン シエンティフィック スクラ 非経口投与用の固体または半固体製剤および遅効性製剤の局部的投与のための装置および調剤プロセス
JP2001519787A (ja) * 1997-04-03 2001-10-23 ポイント バイオメディカル コーポレイション 膀胱内ドラッグデリバリーシステム
US20020055666A1 (en) * 1999-11-12 2002-05-09 Hunter William L. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
JP2019529453A (ja) * 2016-09-23 2019-10-17 ノバルティス アーゲー 腱及び／又は靭帯損傷に使用するためのインダゾール化合物
JP2020523303A (ja) * 2017-06-13 2020-08-06 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 薬物送達用のポリマーペースト組成物
WO2020222139A1 (en) * 2019-04-30 2020-11-05 Trigone Pharma Ltd. Formulations and methods for drug instillation into the bladder and treatment of bladder ailments
WO2021155477A1 (en) * 2020-02-07 2021-08-12 The University Of British Columbia Mucoadhersive polymeric drug delivery compositions and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361490B2 (en) * 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US9248219B2 (en) * 2007-09-14 2016-02-02 Boston Scientific Scimed, Inc. Medical devices having bioerodable layers for the release of therapeutic agents
WO2010088924A1 (en) * 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
DE212011100034U1 (de) * 2010-01-20 2012-07-04 Theracoat Ltd. Material zur Behandlung von inneren Hohlräumen
US8754564B2 (en) * 2010-05-27 2014-06-17 Covidien Lp Hydrogel implants with varying degrees of crosslinking
US9757497B2 (en) * 2011-05-20 2017-09-12 Surmodics, Inc. Delivery of coated hydrophobic active agent particles
WO2013011504A1 (en) * 2011-07-20 2013-01-24 Theracoat Ltd. Materials and method for treating internal body cavities
DK2836200T3 (da) * 2012-04-08 2020-09-21 Urogen Pharma Ltd Termoreversible hydrogelpræparater til anvendelse i behandlingen af lidelser i urothelium
US9801854B1 (en) * 2014-01-17 2017-10-31 Urogen Pharma Ltd. Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer
US20190209502A1 (en) * 2016-09-12 2019-07-11 Evofem, Inc. Combination gel for sexually transmitted infections

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0687758A (ja) * 1992-07-27 1994-03-29 Rhone Merieux Ｌｈｒｈホルモンおよびその類似体を徐々に放出する微小球体の製造方法と、その微小球体と、それを含む製剤
JPH08157370A (ja) * 1994-12-06 1996-06-18 Banyu Pharmaceut Co Ltd フィナステリド含有徐放性組成物
JP2000511161A (ja) * 1996-05-24 2000-08-29 アンジオテック ファーマシュウティカルズ，インコーポレイテッド 身体通路の疾患を処置または予防するための組成物および方法
JP2001506144A (ja) * 1996-12-02 2001-05-15 ソシエ デ コンシェーユ デ ルシェルシェ エ ダプリカシオン シエンティフィック スクラ 非経口投与用の固体または半固体製剤および遅効性製剤の局部的投与のための装置および調剤プロセス
JP2001519787A (ja) * 1997-04-03 2001-10-23 ポイント バイオメディカル コーポレイション 膀胱内ドラッグデリバリーシステム
US20020055666A1 (en) * 1999-11-12 2002-05-09 Hunter William L. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
JP2019529453A (ja) * 2016-09-23 2019-10-17 ノバルティス アーゲー 腱及び／又は靭帯損傷に使用するためのインダゾール化合物
JP2020523303A (ja) * 2017-06-13 2020-08-06 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 薬物送達用のポリマーペースト組成物
WO2020222139A1 (en) * 2019-04-30 2020-11-05 Trigone Pharma Ltd. Formulations and methods for drug instillation into the bladder and treatment of bladder ailments
WO2021155477A1 (en) * 2020-02-07 2021-08-12 The University Of British Columbia Mucoadhersive polymeric drug delivery compositions and methods

Also Published As

Publication number Publication date
KR20240089461A (ko) 2024-06-20
EP4415821A1 (en) 2024-08-21
WO2023062638A1 (en) 2023-04-20
CN118234483A (zh) 2024-06-21
CA3235477A1 (en) 2023-04-20
EP4415821A4 (en) 2025-02-26
AU2022365519A1 (en) 2024-05-02
US20250228767A1 (en) 2025-07-17

Similar Documents

Publication Publication Date Title
JP5986149B2 (ja) 女性の尿失禁を治療するための用具および方法
AU2020265812B2 (en) Formulations and methods for drug instillation into the bladder and treatment of bladder ailments
CN104546691A (zh) 一种关节腔注射用温敏原位凝胶制剂组合物及其制备方法
US12171747B2 (en) Material and method for treating cancer
US10039709B2 (en) Bioadhesive compositions for epithelial drug delivery
CN114177133B (zh) 一种药物缓释载体、缓释药物组合物及其应用
CZ290534B6 (cs) Kombinační prostředky pro léčení bazocelulárního karcinomu nebo aktinických keratóz
JP2001517708A (ja) 炎症性腸疾患を治療するための医薬組成物
EA030133B1 (ru) Фармацевтический препарат контролируемого высвобождения, содержащий гликозаминогликан, для лечения заболеваний кишечника
Abdalla et al. Poloxamer micellar system for intra-articular injection of 15-deoxy-Δ12, 14-prostaglandin J2 with improved bioavailability and anti-inflammatory properties in the temporomandibular joint of rats
US20150290170A1 (en) Ketorolac-containing sustained release drug delivery systems
US20250228767A1 (en) Compositions and methods for drug instillation into the urinary bladder
US20070172507A1 (en) Transluminal drug delivery methods and devices
CN102000339A (zh) 缓释释药的药物载体
US20250275988A1 (en) Formulation for treating urinary system disorders
JP2024539581A5 (cg-RX-API-DMAC7.html)
EP3820439A1 (en) Mucoadhesive dispersion nanoparticle system and method for production the same
WO2025180652A1 (en) Drug delivery systems for instillation in the urinary bladder comprising active pharmaceutical ingredients
Enggi et al. In situ gel forming formulations
CN1709232A (zh) 含有酮洛芬或酮洛芬酯的注射用脂质微球及其制备工艺
Whitehead An investigation of a gastroretentive dosage form

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260714

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260716